Original Article
Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study Banshi Saboo, Gundam Chandrasekhara Reddy1, Subhashchander Juneja2, Ashok Kumar Kedia3, Pravin Manjrekar4, Rahul Rathod4 on behalf of GLOBE Investigators** Consultant Physician, DiaCare Clinic, Ahmedabad, Gujarat, 1Consultant Endocrinologist, G. C. Reddy Clinic, Hyderabad, Andhra Pradesh, 2 Consultant Physician, Heart and Diabetes Care Hospital, Delhi, 3Consultant Physician, Ashok Kumar, Kedia Clinic, Gorakhpur, Uttar Pradesh, 4 Medical Affairs, Bayer Zydus Pharma, Mumbai, Maharashtra, India **Refer to appendix for list of GLOBE investigators
A B S T R A C T Primary objective - evaluate effectiveness and safety of acarbose/metformin fixed dose FDC on glycemic control in Indian T2DM patients in real life clinical setting. Secondary objective - evaluate safety and satisfaction of treatment. Materials and Methods: Open-label, prospective, multicentre, single-arm, non-interventional study. Patients included were aged ≥18 years with T2DM on Acarbose (25/50 mg) and Metformin (500 mg) FDC. Glycemic parameters were recorded during observation. Results: Total 9364 patients were enrolled in the study (mean age, 50.7 years and 60.1% were male). Mean (SD) FBG and PPG was significantly reduced by 42.4 (32.6) mg/dl (P < 0.0001) and 80.2 (49.7) mg/dl (P < 0.0001) respectively at the end of observation. Mean (SD) HbA1c reduced by -1.0% (0.8) to 7.3% (0.7) at the last follow-up visit (P
Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study Banshi Saboo, Gundam Chandrasekhara Reddy1, Subhashchander Juneja2, Ashok Kumar Kedia3, Pravin Manjrekar4, Rahul Rathod4 on behalf of GLOBE Investigators** Consultant Physician, DiaCare Clinic, Ahmedabad, Gujarat, 1Consultant Endocrinologist, G. C. Reddy Clinic, Hyderabad, Andhra Pradesh, 2 Consultant Physician, Heart and Diabetes Care Hospital, Delhi, 3Consultant Physician, Ashok Kumar, Kedia Clinic, Gorakhpur, Uttar Pradesh, 4 Medical Affairs, Bayer Zydus Pharma, Mumbai, Maharashtra, India **Refer to appendix for list of GLOBE investigators
A B S T R A C T Primary objective - evaluate effectiveness and safety of acarbose/metformin fixed dose FDC on glycemic control in Indian T2DM patients in real life clinical setting. Secondary objective - evaluate safety and satisfaction of treatment. Materials and Methods: Open-label, prospective, multicentre, single-arm, non-interventional study. Patients included were aged ≥18 years with T2DM on Acarbose (25/50 mg) and Metformin (500 mg) FDC. Glycemic parameters were recorded during observation. Results: Total 9364 patients were enrolled in the study (mean age, 50.7 years and 60.1% were male). Mean (SD) FBG and PPG was significantly reduced by 42.4 (32.6) mg/dl (P < 0.0001) and 80.2 (49.7) mg/dl (P < 0.0001) respectively at the end of observation. Mean (SD) HbA1c reduced by -1.0% (0.8) to 7.3% (0.7) at the last follow-up visit (P
